Crescom Co., Ltd. (CEO Jae Joon Lee), a company specializing in artificial intelligence medical image analysis solutions, participated in the Korea Hospital Innovation & Medical Equipment Exhibition & Conference 2022 (K-Hospital Fair 2022), it was hold at COEX in Samseong-dong, Seoul from September 29th to October 1st. The company operated a booth to promote the company’s solutions, including MediAI-OA, a knee arthritis severity analysis solution.
In particular, at this K-Hospital Fair 2022, a booth was set up within the NIPA’s Digital Healthcare Special Exhibition area (A10 section) promoted the development of MediAI-OA for knee arthritis diagnosis and AI solution for insurance review by the Health Insurance Review and Assessment (HIRA). The MediAI-OA was developed through the "Artificial Intelligence Fusion (AI+X) Medical Image Reading System Construction Project" supervised by the Information and National IT Industry Promotion Agency (NIPA) and HIRA.
In addition, Crescom displayed three AI image analysis solutions, including ▲ MediAI-BA, a bone age analysis solution, and ▲ MediAI-FX, which can read even scaphoid fractures that are difficult to read, etc.
Crescom's MediAI-OA is a software that can automatically quantify and analyze the severity of arthritis based on the KL grade for knee X-Ray images and is currently in the clinical trial stage. MediAI-BA is a hybrid analysis method of GP and TW3, a bone-age reading technique, and it has been confirmed by the Ministry of Food and Drug Safety (MFDS) that doctors with little experience can more than double the accuracy of reading alone by referring to MediAI-BA. MediAI-FX is the world's first licensed medical device that can read scaphoid fractures, which are especially difficult to read among wrist fractures.
Jae Joon Lee, CEO of Crescom, said, "I am pleased to develop and provide artificial intelligence solutions that can help actual medical sites and insurance screening with the support of NIPA and the Health Insurance Review and Assessment Service. Not only this exhibition, but also in the future, we will do our best to make it widely known to the domestic and foreign medical industries and to provide accurate artificial intelligence medical benefits in a timely manner in overseas markets.”